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Introduction
Serous cystadenomas (SCs) are rare but distinct benign neo-
plasms of pancreas. According to various published articles, 
they comprise 1%–2% of all pancreatic neoplasms and 
10%–29% of pancreatic cystic neoplasms.1–3 SCs are more 
common in the elderly and show a female predominance.4 
Abdominal pain and palpable abdominal mass are the most 
common presenting complaints, but a significant proportion 
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Abstract
Background: Serous cystadenomas of pancreas are rare benign epithelial neoplasms, which predominantly occur in the 
pancreatic body and tail of elderly females. Majority of these tumors have microcystic appearance. Macrocystic and solid 
variants have also been described. A number of more aggressive cystic pancreatic lesions are included in the differential 
diagnosis. Distinction from such lesions is important for optimal management.
Objective: Our aim was to study the clinical and histological features of serous cystadenomas which would be helpful 
in making their correct diagnosis and understanding their behavior.
Methods: We reviewed 23 cases of serous cystadenomas diagnosed in our institution between January 2001 and June 2018.
Results: Mean age at presentation was 53.43 years. Female to male ratio was 4.75:1. Over half (56.5%) of the cases were 
diagnosed incidentally. Abdominal pain was the most common symptom. Body and tail (either alone or in combination) 
were the most common locations. Tumor size ranged from 2 to 16 cm. Central scar was seen in 43.4% cases. Two cases 
were unilocular (macrocystic). Microscopically, all cases showed simple cuboidal to flattened epithelium with round, 
uniform nuclei, and glycogen-rich clear cytoplasm. Focal micropapillae formation was seen in eight cases (34.7%). Surgical 
resection was performed in 82.6% cases. Recurrence occurred in only one single case.
Conclusion: Pancreatic serous cystadenomas are benign neoplasms with excellent prognosis. The tumors showed 
typical morphological features in all cases. Surgical resection was performed in the majority of cases in our study owing 
to lack of optimal and complete radiological workup pre-operatively and the concern for not missing and adequately 
treating pancreatic mucinous cystic neoplasms.
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is asymptomatic and is diagnosed as an incidental finding.5,6 
SCs are associated with von Hippel–Lindau (VHL) disease 
and with many sporadic tumors.4,7,8 Majority of these lesions 
involve the body and/or tail of pancreas.3,9 Radiologically, 
typical cases have a polycystic (honeycomb) appearance 
with a central stellate scar seen in few cases.10
Grossly, majority of SCs are well circumscribed, and the 
cut surface exhibits numerous small cystic spaces filled 
with clear serous fluid (microcystic SCs). These cystic 
spaces are separated by thin fibrous septae, which coalesce 
to form the fibrous stellate scar. Of the other variants, the 
macrocystic/oligocystic variant is poorly demarcated and 
has fewer but larger cystic spaces. The solid variant appears 
as a well-circumscribed solid nodule lacking any grossly 
visible cystic spaces.1,4,11–13 All these macroscopic variants 
are histologically composed of characteristic flattened to 
cuboidal, glycogen-containing epithelial cells with round 
uniform nuclei. Intervening stroma shows a network of 
small vascular channels.1,3,4
SCs run a benign, indolent clinical course and have an 
excellent prognosis. They are slow growing, malignant pro-
gression is rare, and disease mortality is almost nil. Surgical 
excision is curative but is required only in minority of cases 
when tumors are large or causing significant (or related) 
symptoms or when preoperative diagnosis was uncertain in 
spite of extensive workup including computed tomography 
(CT) scan, magnetic resonance imaging (MRI), and endo-
scopic ultrasonography. It is also required in the excep-
tional cases where concern of malignancy exists. Large 
majority of these tumors may require conservative manage-
ment only.14–16 Recurrence is seen rarely in locally aggres-
sive tumors.5
The aim of our study was to describe the clinical and 
histopathological features of SCs of pancreas which would 
be helpful in making their correct diagnosis and under-
standing their behavior.
Materials and methods
We retrieved 23 cases of SC of pancreas from the surgical 
pathology database of the Section of Histopathology, Aga 
Khan University Hospital reported between January 2001 
and June 2018 through “Integrated Laboratory Management 
System (ILMS)” software. Clinical information regarding 
age, sex, exact location in pancreas, presenting complaints, 
tumor size, and gross appearance was obtained from the 
surgical pathology reports. Hematoxylin and Eosin (H&E)-
stained microscopic glass slides were reviewed by two 
authors (M.U.T. and N.U.D.) to assess histological features 
such as micropapillary architecture, epithelial cell mor-
phology, and calcification and extension into peripancreatic 
adipose tissue. Follow-up information for nine patients 
treated at our institution was available from the patients’ 
records which were reviewed. These records contained 
findings of CT scans performed on each follow-up visit. 
Follow-up information for patients treated at other institu-
tions was obtained from the patients verbally via telephonic 
conversation.
Results
Ages of patients at the time of presentation ranged from 23 
to 79 years with mean and standard deviation (SD) of 
53.43 years ± 14.88 and 50 years. Of the 23 patients, 19 
(82.6%) were females and 4 (17.4%) were males. The F:M 
ratio was median of 4.7:1. Symptoms related to pancreatic 
lesions were seen in 10 cases (43.5%) with abdominal pain 
being the most common (5 cases or 21.7%), followed by 
jaundice (3 or 13%). None of the 19 female patients in the 
study had any history of alcohol consumption and/or smok-
ing. Clinical information regarding body mass index (BMI) 
was not available in any of the cases. Preoperative serum 
carcinoembryonic antigen (CEA) levels were available in 
two cases and were within normal limits. Serum CA 19-9 
levels were available in three patients and were found to be 
elevated in two cases. In five cases (21.7%), the tumors 
were incidentally identified during routine radiological 
examination or radiological examination done for detection 
of non-pancreatic lesions (Table 1). Approximately, two-
thirds were located in body and tail of pancreas. Surgical 
resection was performed in 19 of 23 cases (82.6%). Distal 
pancreatectomy with splenectomy was the commonest type 
of surgical resection performed (Table 1). Tumor size 
ranged from 2 to 16 cm in maximum dimension with 
median and mean size of 5.5 and 6.4 cm ± 4.6 SD, respec-
tively. According to the preoperative radiological films, 
majority of these lesions presented as well-defined, 
hypodense, cystic masses, mainly involving the body and 
tail of the pancreas. In two cases, the lesions showed pre-
dominantly solid appearance. Cystic locules of variable 
sizes, internal septations, calcifications, and peripancreatic 
fat stranding were also observed in few cases (Figure 1(a)). 
However, convincing radiological evidence of infiltration 
into retroperitoneal fat was seen in only a single case. 
Grossly, the lesions in our study were well circumscribed 
with smooth or bosselated outer surfaces and cystic spaces 
of variable sizes filled with clear or straw colored serous 
fluid on cut surface. In few cases, cut surfaces showed solid 
areas without grossly visible lumina. A gray white, fibrotic, 
variably calcified central scar was seen in 10 cases (43.4%). 
The cystic spaces ranged from 1 mm to 3 cm in diameter, 
but the majority was smaller than 1 cm (Figure 1(b)). Of 23 
cases, 2 (8.6%) were unilocular (Figure 2). Macroscopic 
extension into retroperitoneal fat was seen in a single case 
which had radiological evidence of retroperitoneal fat 
involvement.
Microscopically, cystic spaces in all cases were lined 
by a single layer of flattened to cuboidal epithelial cells 
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with moderate amount of clear to faintly eosinophilic 
cytoplasm. One case showed ciliated cuboidal epithelium 
while another showed decapitation secretions. Epithelial 
cell nuclei were round, uniform, and centrally placed 
(Figure 3(a) and (b)). Significant nuclear atypia or mitotic 
activity was not seen in any of the cases. Cytoplasmic gly-
cogen granules were highlighted on periodic acid Schiff 
(PAS) stain and were washed out with diastase reaction 
(Figure 3, inset). In few cases, micropapillae formation 
was seen focally (Figures 3(c) and (d)). Intraluminal 
eosinophilic secretions were seen in some cases (Figure 
4(a)). Since H&E staining and PAS with diastase stains 
were sufficient for establishing the diagnosis, immuno-
histochemical (IHC) stains were not performed. Central 
stellate scar, when present, was composed histologi-
cally of acellular fibrous tissue with variable degree of 
hyalinization and edematous change. Scattered foci of 
dystrophic calcification, hemorrhage, and collections 
of hemosiderin macrophages were also identified 
(Figure 4(b) and (c)). In addition to the case with radi-
ological and macroscopic evidence of retroperitoneal 
fat involvement, focal extension into peripancreatic fat 
and entrapment of native pancreatic tissue was seen 
microscopically in four cases (17.4%) (Figure 4(d) and 
Table 1).
Follow-up was available in all 23 cases. Follow-up dura-
tion ranged from 4 to 183 months with mean follow-up of 
77.8 months ± 62.2 SD and median of 58 months. None of 
the patients received adjuvant chemotherapy or radiother-
apy. Only one patient (with tumor extension into retroperi-
toneal fat) developed local recurrence 4 years after initial 
surgery. None of the patients developed metastasis or died 
of disease. One patient died of liver disease (unrelated to 
pancreatic tumor) 1 year after the diagnosis of SC. 
Compared to 23 cases of SC, 11 cases of pancreatic muci-
nous cystic neoplasms (MCNs) and 2 cases of intraductal 
papillary mucinous neoplasm (IPMN) were diagnosed dur-
ing the study period (January 2001–June 2018). During the 
same period, 115 cases of invasive pancreatic adenocarci-
noma and 177 cases of ampullary adenocarcinoma were 
diagnosed and managed.
Table 1. Summary of clinical and histological features of serous 
cystadenoma of pancreas patients (n = 23).
Tumor location Frequency, n (%)
Body and tail of pancreas 6 (26.1)
Body of pancreas only 2 (8.6)
Tail of pancreas only 5 (21.7)
Head of pancreas 6 (26.1)
Uncinate process 1 (4.3)
Site not mentioned 3 (13.0)
Surgical procedure and type of biopsy Frequency
Surgical resection 18 (81.8)
Distal pancreatectomy 13 (59)
Whipple’s procedure 4 (17.4)
Enucleation 1 (4.3)
Wedge/incisional biopsy 4 (17.4)
Block received for second opinion 1 (4.3)
Splenectomy 11 (50)
Histological features Frequency
Micropapillae formation 8 (34.7)
Calcification 7 (30.4)
Hemorrhage 4 (17.4)
Lymphocytic infiltration 4 (17.4)
Peripancreatic fat extension 4 (17.4)
Entrapment of native pancreatic tissue 8 (34.7)
List of other non-pancreatic lesions (5 cases)
Ovarian thecoma
Gastric gastrointestinal stromal tumor (GIST)
Renal oncocytoma and uterine fibroid
Hepatocellular carcinoma/liver cirrhosis
Tuberculous lymphadenitis
Figure 1. (a) CT scan abdomen showing a well-defined, solid, hypodense mass lesion in pancreatic body with central popcorn-like 
amorphous calcification. (b) Gross appearance of serous cystadenoma. Central fibrotic scar is evident along with multiple small-sized 
cystic spaces. Normal pancreatic tissue is present at the periphery.
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Discussion
A variety of cystic lesions can occur in the pancreas and 
range from benign entities such as pseudocysts and SCs to 
tumors with potential for aggressive behavior such as 
MCNs and IPMNs. Moreover, solid pancreatic tumors such 
as solid pseudopapillary tumor and invasive ductal adeno-
carcinoma can acquire a cystic appearance due to degenera-
tive or necrotic changes.17 In 1978, SCs of pancreas were 
separated from pancreatic mucinous cystic neoplasms.18,19 
Based on the IHC and ultrastructural findings, SCs are 
believed to be derived from intercalated duct cell or cen-
troacinar cell lineage.20,21
SCs occur over a wide age range. Various published 
studies, have reported age ranges from 24 to 93 years with 
mean age at presentation in sixth and seventh decades.1,4 
We also observed similar age distribution in our series, as 
majority (65.2%) of our patients were in their fifth to sev-
enth decades when diagnosed. Females are three times 
more commonly affected than males.5 In our study also, 
marked female preponderance was noted. These tumors 
can present with abdominal pain, palpable mass, vomiting, 
nausea, weight loss, and so on. Jaundice is uncommon but 
can be seen in tumors involving the head of pancreas sec-
ondary to occlusion of common bile duct.1,5,20 However, 
almost half are detected incidentally during radiological 
examination performed for detection of possible non-
pancreatic lesions.14 It is possible nowadays to accurately 
diagnose SCs by performing MRI or endoscopic ultra-
sound, and so on, without need of biopsy other invasive tech-
niques.16 In our study, over 55% patients were 
asymptomatic and were diagnosed incidentally. Abdominal 
Figure 2. Low-power view of unilocular variant exhibiting a 
single large cystic locule lined by single layer of cells. Inset: PAS 
special stain highlighting intracytoplasmic glycogen granules.
Figure 3. Microscopic features of serous cystadenoma: (a) low-power view showing small cystic space lined by single layer of 
cuboidal cells, (b) high-power view showing cuboidal cells with moderate amount of lightly eosinophilc granular cytoplasm and 
centrally placed, rounded, uniform nuclei, (c) low-power view of micropapillae, and (d) high-power view of micropapillae.
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pain, jaundice, abdominal mass, nausea, and vomiting were 
the main symptoms noticed in our patients. Only two 
patients in our series (with tumors in pancreatic head) pre-
sented with jaundice. Tumor sizes in published studies have 
ranged from 1 to 25 cm with mean size of 6 cm.1 In our 
series also, wide range was seen in tumor size from as small 
as 2 cm to as large as 16 cm. Grossly, the usual microcystic 
forms appear as well-circumscribed lesions with smooth 
rounded or bosselated outer surfaces. Cut surfaces show 
numerous microcysts with irregular contours and diameters 
ranging from less than a millimeter to more than a centim-
eter.1 A fibrous stellate scar with or without calcification is 
seen in up to 30% cases and provides a useful diagnostic 
clue.3 In our study, central scar was seen in 43.4% tumors. 
One of the recent studies divided the microcystic form of 
SC into “microcystic, classical type” which have very few 
larger cystic locules (measuring in centimeters) and “micro-
cystic with prominent macrocystic component” which have 
a prominent component of large cystic locules, although the 
usual microcystic pattern still predominates.4 The less-
common macrocystic variant was described in older studies 
as “serous oligocystic ill-demarcated adenoma of pancreas.” 
Macrocystic variants are poorly demarcated and contain 
larger cystic locules, which measure more than a centimeter 
in diameter each and are typically less than 10 in number. 
In some cases, the lesion comprises of a single locule 
only.1,4,11,12 Such unilocular lesions occur more frequently 
in pancreatic head of elderly males.1,2 However, a recent 
study on a larger cohort of cases reported that this variant 
occurs in a younger age group as compared to microcystic 
form (50 vs 61 years) but shows similar female predomi-
nance and predilection for body and tail region.4 In our 
cohort, two patients had unilocular tumors. One of these 
patients was a 23-year-old female with tumor in pancreatic 
tail. The other patient was a 68-year-old male with tumor in 
the head of the pancreas. Solid variant of SC is rare, and so 
far, only 20 sporadic cases have been reported. It comprised 
only 2% of cases in a large study on SCs. It has no gender 
or site (head vs body and tail) predilection and usually 
occurs in the sixth and seventh decades of life. In most 
cases, tumor size is between 2 and 4 cm. Grossly, these are 
well-circumscribed, grayish brown nodules with shiny cut 
surfaces, and do not have a central scar. Microscopically, 
the solid variant of SC is composed of closely packed, 
small, uniform tubules, and acini with little or no lumina 
formation.4,22 Turcotte et al.23 reported 10 (18.2%) cases of 
solid microcystic SC in a cohort of 55 VHL patients with 
SC. A few cases in our study grossly showed solid areas, 
but this appearance was not predominant on the cut surface 
of the lesion and these tumors did not meet the criteria for 
“solid variant” of SC. Fine needle aspiration of these lesions 
does not provide a good yield of diagnostic material due to 
Figure 4. Microscopic features of serous cystadenoma: (a) eosinophilic secretions in cyst lumina, (b) central scar exhibiting 
hyalinization and calcification, (c) hemorrhage and hemosiderin-laden macrophages, and (d) normal pancreatic tissue entrapped 
within cyst walls/septae.
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paucicellular nature of these lesions and cohesiveness of 
the epithelial cells.4,24
Pancreatic lesions are seen in 35%–70% cases of VHL 
disease.25 Majority of these lesions are asymptomatic sim-
ple cysts, which usually do not require excision. According 
to World Health Organization (WHO) classification of pan-
creatic serous neoplasms, “VHL-associated serous cystic 
neoplasms” are a group of lesions, which can appear in 
microcystic, macrocystic, and solid forms. In VHL disease 
patients, they can diffusely involve pancreas or occur as 
multiple lesions. Microscopically, they have simple cuboi-
dal epithelial lining of glycogen-rich, clear cells.1,23 Apart 
from their association with pancreatic neuroendocrine 
tumors (PanNET) in VHL disease, they are also seen in 
patients with various other neoplastic and non-neoplastic 
pancreatic and non-pancreatic lesions.1,3,4 Most frequent 
molecular abnormalities observed in sporadic SC cases 
include allelic losses on 10q (50%) and 3p (40%). In addi-
tion, somatic inactivating mutations of VHL gene are 
observed in 22% of sporadic SCs.26 We encountered a num-
ber of non-pancreatic lesions in our group of patients (Table 
1). Molecular testing for VHL disease was not performed in 
any of our cases, since it was not available in any laboratory 
in the country. Association of these neoplastic lesions with 
SCs has not been explained until now. However, in our 
opinion, frequent simultaneous occurrence of these lesions 
raises a possibility of their common association with some 
other syndrome.
In the majority of cases, the diagnosis is straightforward 
due to peculiar cytomorphology. However, these tumors 
may show heterogeneity in their histological features. We 
observed heterogeneous features including micropapillae 
formation, calcification, hemorrhage, lymphocytic infiltra-
tion, peripancreatic fat extension, and entrapment of native 
fat in a number of our cases. In cases with denuded epithe-
lial lining, benign vascular lesions such as lymphangioma 
and hemangioma need to be considered in the differential 
diagnosis. The presence of smaller tubules with intact epi-
thelium at the periphery provides a diagnostic clue. The 
presence of cytoplasmic glycogen granules and lack of 
cytoplasmic mucin rules out other pancreatic mucinous 
cystic neoplasms. Metastatic renal cell carcinoma (RCC) is 
another important differential diagnosis in cases where the 
tubules are smaller and closely packed. Clinical history and 
PAX-8 expression in RCC help in distinction between the 
two entities. PanNETs and clear-cell sugar tumors are other 
close differentials, especially in solid variant of SC. 
PanNETs occurring in patients with VHL disease exhibit 
clear-cell morphology, but expression for neuroendocrine 
markers helps in differentiation from pancreatic SCs.1 SCs 
demonstrate positive expression for epithelial membrane 
antigen (EMA), cytokeratins, α-inhibin, MUC6 and 
MUC1 stains, and negative expression for neuroendo-
crine markers.20 All cases in our study showed typical 
cuboidal to flattened epithelial cells with round, uniform 
nuclei, and clear, glycogen-rich cytoplasm. The epithelial 
lining can exhibit focal pseudopapillae formation. The cen-
tral scar may show hyalinization, edema, hemorrhage, 
chronic inflammation, and calcification in variable propor-
tions. We have reported the frequency and percentages of 
these features in our cases in detail (Table 1). Few studies 
have described these morphological features in such detail. 
Despite gross demarcation and circumscription, 4 (17.4%) 
tumors in our study showed focal extension into the peri-
pancreatic fat on microscopic examination. However, none 
of these tumors had recurred at the time of last follow-up. 
The only case in our study which showed recurrence had 
radiological and macroscopic evidence of retroperitoneal 
fat extension. We feel that surgical excision with clear mar-
gins is sufficient to prevent recurrence.
Complete surgical resection is curative in all cases of 
pancreatic SC but is recommended only in a small minority 
of cases in which preoperative diagnosis remained uncer-
tain in spite of extensive radiological workup or when 
tumors were large in size or were causing significant tumor-
related symptoms. It is also recommended in the excep-
tional cases in which a concern of malignancy exists.16 
However, in poor developing countries such as Pakistan 
and Afghanistan, radiological facilities for accurate non-
invasive diagnosis of pancreatic neoplasms are suboptimal 
in most areas, and the importance of not missing and ade-
quately treating mucinous pancreatic neoplasms, which 
have aggressive malignant potential, means that at least for 
the near future, surgical resection may continue to be per-
formed for the majority of pancreatic cystic neoplasms 
regardless of whether they are serous or mucinous. In view 
of the postoperative morbidity and mortality associated 
with pancreatic surgeries, asymptomatic, and uncompli-
cated small tumors are managed conservatively. Surgical 
excision may be recommended for symptomatic and larger 
(>4 cm) tumors.14,16 Of the 23 patients in our study, 16 had 
tumors larger than 4 cm in diameter. In the remaining three 
cases in which resection was performed, the diameter was 
less than 4 cm. Since surgery in these three cases was per-
formed outside our institution, exact indication for surgery 
is not known. Although majority of pancreatic SCs are 
benign, few are locally aggressive and sometimes extend 
into the peripancreatic tissues. These locally aggressive 
SCs have a greater potential for recurrence and therefore, 
warrant close follow-up.5 Most of our patients underwent 
surgical resection, and the exact type of surgical procedure 
was chosen on the basis of exact location of these tumors in 
the pancreas. Four patients only had incisional biopsy and 
the disease remained stable (until the time of last follow-
up). One patient in our series with a pancreatic head tumor 
and radiological and gross extension into the retroperito-
neal fat developed recurrence 4 years after initial resection 
of tumor.
Serous cystic neoplasms are slow-growing tumors with 
excellent prognosis. The incidence of malignancy was 
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reported as 3% in a large study.27 According to the WHO 
classification, distant metastasis is the only criterion for 
malignancy.1 A recent large study by Reid et al.4 showed 
that cases of SC of pancreas with hepatic involvement actu-
ally represented synchronous and metachronous multifocal 
primary hepatic and pancreatic SCs rather than hepatic 
extension/metastasis from the pancreatic tumor. All patients 
in our study had a very good clinical course with not a sin-
gle instance of metastasis or tumor-related death even sev-
eral years after surgical removal.
It is absolutely essential to make an accurate diagnosis. 
Confusion with pancreatic ductal adenocarcinomas may be 
catastrophic for the patient. Ductal adenocarcinomas of the 
pancreas are highly aggressive tumors and the vast majority 
have already spread beyond the pancreas at the time of 
diagnosis. They are fatal in almost all cases with mean sur-
vival times ranging from 3 to 5 months in untreated patients 
and 10–20 months after surgical resection. The tumors are 
surgically resectable at the time of diagnosis in only 10%–
20% cases. Current newly developed neoadjuvant treat-
ments are employed in unresectable cases. However, even 
adjuvant chemotherapy with gemcitabine or 5-fluorouracil 
prolongs survival times very slightly. On the other hand, 
SCs have excellent prognosis and can often be managed 
conservatively and as discussed above requires surgical 
resection in only selected cases. Neoadjuvant treatments 
are definitely not required, and in case of incorrect diag-
nosis, patients may be subjected to unnecessary, even 
harmful surgery (potentially significant postoperative 
morbidity and mortality especially in elder patients) and 
totally unnecessary getting harmful neoadjuvant chemo-
therapy. The importance of correct diagnosis and the need 
to distinguish SC from pancreatic adenocarcinomas can-
not be overemphasized.1,28–33
Conclusion
SCs of pancreas are benign pancreatic neoplasms with dis-
tinct clinical, radiological, and histological features in the 
majority of cases. Distinction from more aggressive pan-
creatic cystic lesions is important and can be done by radio-
logical and, in some cases, by histologic evaluation of 
adequate biopsy material. Clinical course is excellent. 
Recurrence is uncommon and tumor-related deaths are 
almost nil. Large majority of cases require only conserva-
tive initial management, and surgical resection is required 
only in a minority of cases. However, in poor developing 
countries such as ours, surgical resection may still be per-
formed in the majority of cases owing to lack of optimum 
radiological services hindering non-invasive diagnosis of 
these tumors and the importance of ensuring that mucinous 
pancreatic neoplasms owing to their aggressive potential 
are not missed and are treated adequately.
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